| 25.73 1.3 (5.32%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.51 | 1-year : | 40.31 |
| Resists | First : | 29.54 | Second : | 34.51 |
| Pivot price | 24.88  |
|||
| Supports | First : | 22.98 | Second : | 18.93 |
| MAs | MA(5) : | 25 |
MA(20) : | 25.22 |
| MA(100) : | 29.67 |
MA(250) : | 27.47 |
|
| MACD | MACD : | -0.8 |
Signal : | -1 |
| %K %D | K(14,3) : | 55.6 |
D(3) : | 55.6 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 40.65 | Low : | 12.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TYRA ] has closed below upper band by 36.6%. Bollinger Bands are 0.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.87 - 25.97 | 25.97 - 26.04 |
| Low: | 24.15 - 24.27 | 24.27 - 24.36 |
| Close: | 25.55 - 25.74 | 25.74 - 25.89 |
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Fri, 18 Sep 2026
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Unveiling a 97.71% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Thu, 17 Sep 2026
Tyra Biosciences (NASDAQ: TYRA) CEO lifts stake to 1,438,495 shares - Stock Titan
Thu, 17 Sep 2026
Stock grant lifts Tyra Biosciences (NASDAQ: TYRA) finance VP stake to 11,258 shares - Stock Titan
Thu, 17 Sep 2026
Tyra Biosciences (TYRA) investor uses capped warrants to reach 19.99% stake - Stock Titan
Thu, 17 Sep 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA - PR Newswire
Wed, 16 Sep 2026
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 117.4 (%) |
| Shares Short | 9,690 (K) |
| Shares Short P.Month | 9,930 (K) |
| EPS | -2.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.5 % |
| Return on Equity (ttm) | -45.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -110 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -10.77 |
| PEG Ratio | 0 |
| Price to Book value | 4.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|